The study was unable to include a control group of pregnant women with normal ongoing pregnancies due to the financial barriers associated with genetic testing in Romania, where such tests are not covered by government or insurance programs, limiting our ability to comprehensively assess the prevalence of MTHFR mutations and other thrombophilia mutations among the wider population. This evidence concerns the gene MTHFR and Rare hereditary thrombophilia.